VanEck Biotech ETF (NASDAQ:BBH – Get Free Report) shares hit a new 52-week high during mid-day trading on Thursday. The company traded as high as $247.83 and last traded at $247.7640, with a volume of 5,352 shares traded. The stock had previously closed at $241.07.
VanEck Biotech ETF Trading Up 2.8%
The company has a 50-day moving average of $235.08 and a 200 day moving average of $207.96.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of BBH. Kestra Advisory Services LLC boosted its stake in shares of VanEck Biotech ETF by 3.0% in the 1st quarter. Kestra Advisory Services LLC now owns 3,405 shares of the company’s stock valued at $640,000 after purchasing an additional 98 shares in the last quarter. Janney Montgomery Scott LLC increased its position in shares of VanEck Biotech ETF by 3.4% during the 1st quarter. Janney Montgomery Scott LLC now owns 3,040 shares of the company’s stock worth $572,000 after purchasing an additional 100 shares in the last quarter. Coastline Trust Co acquired a new stake in shares of VanEck Biotech ETF during the 3rd quarter worth about $46,000. CoreCap Advisors LLC bought a new position in VanEck Biotech ETF during the 3rd quarter valued at about $46,000. Finally, First PREMIER Bank bought a new position in VanEck Biotech ETF during the 2nd quarter valued at about $91,000. 32.05% of the stock is currently owned by institutional investors and hedge funds.
About VanEck Biotech ETF
The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.
Featured Stories
- Five stocks we like better than VanEck Biotech ETF
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
- Fastenal Flashes Bullish Signal as Uptrend Holds Despite Margin Pressure
- Synopsys Signals Confidence With $1B Accelerated Buyback, Analysts Raise Targets
Receive News & Ratings for VanEck Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
